Spark Therapeutics, Inc.

Spark Therapeutics, Inc. is a biotechnology company based in the United States with a mission to unlock the power of gene therapy to accelerate healthcare transformation. Since its founding in 2013, the company has been committed to bringing a wide range of expertise to build a fully integrated gene therapy company focused on inherited retinal diseases (IRDs), neurodegenerative diseases, and diseases that can be addressed by targeting the liver, such as hemophilia. Spark Therapeutics, Inc. is dedicated to embracing challenges and uncertainty to create a world where no life is limited by disease. As of 03 August 2017, the company received a $380.40M post-IPO equity investment, demonstrating its potential and attracting significant support. The company's dedication to innovation, vision, and commitment to transforming healthcare are evident in its slogan, "Our mission is to unlock the power of gene therapy to accelerate healthcare transformation." As a member of the Roche Group, Spark Therapeutics, Inc. is at the forefront of pioneering gene therapy and has set its sights on bringing this innovative treatment to people worldwide. As a venture capital investor, it is important to recognize the potential impact and opportunities presented by Spark Therapeutics, Inc. in the field of gene therapy and biotechnology. Its dedication to addressing critical health challenges and its resilience in breaking barriers make it an attractive prospect for investment and a significant player in the healthcare innovation landscape.